{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:00:42Z","timestamp":1764745242335,"version":"3.46.0"},"reference-count":22,"publisher":"Touch Medical Media, Ltd.","issue":"2","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<p\/>","DOI":"10.17925\/hi.2021.15.2.65","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T12:54:12Z","timestamp":1643720052000},"page":"65","source":"Crossref","is-referenced-by-count":1,"title":["XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: \u2018The New Normal\u2019?"],"prefix":"10.17925","volume":"15","author":[{"given":"Niels MR van der","family":"Sangen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Cardiology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter J","family":"Kikkert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Cardiology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 PS","family":"Henriques","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Cardiology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimmer EPM","family":"Claessen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Cardiology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.\n                      N Engl J Med\n                      . 2003;349:1315\u201323.","DOI":"10.1056\/NEJMoa035071"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.\n                      N Engl J Med\n                      . 2004;350:221\u201331.","DOI":"10.1056\/NEJMoa032441"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.\n                      N Engl J Med\n                      . 2002;346:1773\u201380.","DOI":"10.1056\/NEJMoa012843"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern.\n                      Circulation\n                      . 2007;115:1440-55;discussion 55.","DOI":"10.1161\/CIRCULATIONAHA.106.666800"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Farb A, Boam AB. Stent thrombosis redux-the FDA perspective.\n                      N Engl J Med\n                      . 2007;356:984\u20137.","DOI":"10.1056\/NEJMp068304"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Mitsis A, Valgimigli M. Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy.\n                      Expert Rev Med Devices\n                      . 2020;17:383\u201390.","DOI":"10.1080\/17434440.2020.1747434"},{"key":"ref7","unstructured":"ClinicalTrials.gov. XIENCE 28 Global Study. ClinicalTrials.gov Identifier: NCT03355742. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03355742 (accessed 19 October 2021)."},{"key":"ref8","unstructured":"ClinicalTrials.gov. XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients. ClinicalTrials.gov Identifier: NCT03218787. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03218787 (accessed 19 October 2021)."},{"key":"ref9","unstructured":"ClinicalTrials.gov. XIENCE 28 USA Study. ClinicalTrials.gov Identifier: NCT03815175. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03815175 (accessed 19 October 2021)."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.\n                      Eur Heart J\n                      . 2019;40:2632\u201353.","DOI":"10.1093\/eurheartj\/ehz372"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Krucoff MW, Rutledge DR, Gruberg L, et al. A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study).\n                      JACC Cardiovasc Interv\n                      . 2011;4:1298\u2013309.","DOI":"10.1016\/j.jcin.2011.08.010"},{"key":"ref12","unstructured":"ClinicalTrials.gov. XIENCE V\u00ae Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V\u00ae USA Long Term Follow-up Cohort) (XVU-LTF). ClinicalTrials.gov Identifier: NCT01120379. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01120379 (accessed 19 October 2021)."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Natsuaki M, Morimoto T, Yamamoto E, et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial.\n                      Cardiovasc Interv Ther\n                      . 2016;31:196\u2013209.","DOI":"10.1007\/s12928-015-0366-9"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial.\n                      JAMA\n                      . 2019;321:2414\u201327.","DOI":"10.1001\/jama.2019.8145"},{"key":"ref15","unstructured":"ClinicalTrials.gov. Short and Optimal Duration of Dual Antiplatelet Therapy Study (STOPDAPT). ClinicalTrials.gov Identifier: NCT01659034. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01659034 (accessed 22 October 2021)."},{"key":"ref16","unstructured":"ClinicalTrials.gov. Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial (RESET). ClinicalTrials.gov Identifier: NCT01035450. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01035450 (accessed 19 October 2021)."},{"key":"ref17","unstructured":"ClinicalTrials.gov. ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study (STOPDAPT-2). ClinicalTrials.gov Identifier: NCT02619760. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02619760 (accessed 19 October 2021)."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC).\n                      Eur Heart J\n                      . 2019;41:407\u201377.","DOI":"10.1093\/eurheartj\/ehz825"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Giustino G, Chieffo A, Palmerini T, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI.\n                      J Am Coll Cardiol\n                      . 2016;68:1851\u201364.","DOI":"10.1016\/j.jacc.2016.07.760"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Yeh RW, Kereiakes DJ, Steg PG, et al. Lesion complexity and outcomes of extended dual antiplatelet therapy after percutaneous coronary intervention.\n                      J Am Coll Cardiol\n                      . 2017;70:2213\u201323.","DOI":"10.1016\/j.jacc.2017.09.011"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Costa F, Van Klaveren D, Feres F, et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting.\n                      J Am Coll Cardiol\n                      . 2019;73:741\u201354.","DOI":"10.1016\/j.jacc.2018.11.048"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"van der Sangen NMR, Rozemeijer R, Chan Pin Yin D, et al. Patient-tailored antithrombotic therapy following percutaneous coronary intervention.\n                      Eur Heart J\n                      . 2021;42:1038\u201346.","DOI":"10.1093\/eurheartj\/ehaa1097"}],"container-title":["Heart International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchcardio.com\/interventional-cardiology\/journal-articles\/xience-implantation-followed-by-short-dual-antiplatelet-therapy-the-new-normal\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:58:24Z","timestamp":1764745104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchcardio.com\/interventional-cardiology\/journal-articles\/xience-implantation-followed-by-short-dual-antiplatelet-therapy-the-new-normal\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"alternative-id":["HI.2021.15.2.65"],"URL":"https:\/\/doi.org\/10.17925\/hi.2021.15.2.65","relation":{},"ISSN":["2036-2579"],"issn-type":[{"type":"print","value":"2036-2579"}],"subject":[],"published":{"date-parts":[[2021]]}}}